



Índice de intervenções por tema

B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY

- CO 46 CLINICAL SIGNIFICANCE OF RIGHT VENTRICULAR PULMONARY ARTERIAL UNCOUPLING IN HYPERTROPHIC CARDIOMYOPATHY
- CO 47 CAN WE BETTER SELECT PATIENTS WITH CRYPTOGENIC STROKE FOR IMPLANTABLE LOOP RECORDERS? - THE IMPORTANCE OF ATRIAL STRAIN AS A PREDICTOR OF SUBCLINICAL ATRIAL FIBRILLATION
- CO 48 ASSESSING THE UTILITY OF THE INCREASED WALL THICKNESS SCORE IN DIAGNOSING ATTR CARDIOMYOPATHY - A VALIDATION STUDY
- PO 28 ANALYZING THE RVOT ENVELOPE IN PULMONARY HYPERTENSION - SIMPLICITY IS KEY
- PO 29 AI AUTOMATED ECHOCARDIOGRAPHIC MEASUREMENTS - IS THIS THE FUTURE?
- PO 30 THREE-DIMENSIONAL ECHOCARDIOGRAPHY FOR THE ASSESSMENT OF RIGHT VENTRICULO-ARTERIAL COUPLING IN PRE-CAPILLARY PULMONARY HYPERTENSION.
- PO 31 NONINVASIVE MEASUREMENT OF MEAN PULMONARY ARTERY PRESSURE THROUGH ECHOCARDIOGRAPHY - IS IT A RELIABLE ALTERNATIVE?
- PO 32 THE FLUTTER-BY EFFECT IN TRANSCATHETER AORTIC VALVE IMPLANTATION BIOPROSTHESIS
- PO 33 PERFORMANCE OF THREE DIMENSIONAL RIGHT VENTRICULAR EVALUATION AND RIGHT VENTRICULAR STRAIN IN SICKLE CELL DISEASE PATIENTS
- PO 34 ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION HEMODYNAMIC EVALUATION - A SILVER LINING
- PO 35 MYOCARDIAL WORK IN ATHLETES: A NOVEL APPROACH TO DIFFERENTIATE ATHLETIC HEART ADAPTATIONS FROM CARDIOMYOPATHY?
- PO 36 ASSESSING THE VALUE OF ROUTINE CONTRAST ECHOCARDIOGRAPHY FOR LEFT VENTRICULAR THROMBUS SCREENING IN ANTERIOR ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS

B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY

- CO 49 RADIOMIC FEATURES OF EPICARDIAL ADIPOSE TISSUE IN AF PROGRESSION
- CO 98 COMPUTED TOMOGRAPHY-DERIVED MYOCARDIAL EXTRACELLULAR VOLUME AS A PROGNOSIS PREDICTOR IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 303 COMPARISON OF RADIOMIC FEATURE STABILITY BETWEEN HUMAN SEGMENTATIONS AND AUTOMATIC SEGMENTATION TOOLS.
- PO 304 CT-RADIOMIC FEATURES OF EPICARDIAL ADIPOSE TISSUE IN AF RECURRENCE AFTER CATHETER ABLATION
- PO 305 BEYOND EUROSORE II - THE INTERPLAY BETWEEN EUROSORE II AND AORTIC CALCIFICATION AS PREDICTORS OF CLINICAL OUTCOMES IN POSTOPERATIVE CARDIAC SURGERY
- PO 306 RELATIONSHIP BETWEEN THE NEW SCORE2-DIABETES AND CORONARY ATHEROSCLEROTIC BURDEN - A CORONARY CALCIUM SCORE CORRELATION STUDY
- PO 307 CAN AORTIC CALCIUM SCORE PREDICT NEW CONDUCTION DISTURBANCES IN POS-TRANSCATHETER AORTIC VALVE IMPLANTATION?
- PO 308 THE ROLE OF PERICARDIAL FLUID CT RADIOMIC ANALYSIS TO DIFFERENTIATE EXUDATE FROM TRANSUDATE.

B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE

- CO 50 PREDICTORS OF LV REVERSE REMODELING AFTER SAVR: INSIGHTS FROM A PROSPECTIVE TTE AND CMR STUDY IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 213 CARDIAC MAGNETIC RESONANCE ACCESS AND CLINICAL RELEVANCE IN MINOCA: INSIGHTS FROM A TERTIARY CENTER EXPERIENCE
- PO 355 AUTOMATIC MEASUREMENT OF ATRIAL LONGITUDINAL SHORTENING BY ARTIFICIAL INTELLIGENCE IN CMR IN THE ASSESSMENT OF LEFT ATRIAL FUNCTION IN PATIENTS WITH HCM AND MCD
- PO 356 HISTOPATHOLOGICAL MYOCARDIAL CHANGES IN PATIENTS WITH SEVERE AORTIC STENOSIS REFERRED FOR SURGICAL VALVE REPLACEMENT: A CMR CORRELATION STUDY
- PO 357 SAFETY OF MAGNETIC RESONANCE IMAGING IN PATIENTS WITH COMPATIBLE CARDIAC IMPLANTABLE ELECTRONIC DEVICES: A SAFETY AND ACUTE PERFORMANCE EVALUATION
- PO 358 CARDIOVASCULAR MAGNETIC RESONANCE VS HISTOPATHOLOGIC STUDY FOR BENIGN AND MALIGNANT CARDIAC TUMOURS DIAGNOSIS - A SYSTEMATIC REVIEW AND METANALYSES
- PO 359 CORRELATION BETWEEN ELECTROCARDIOGRAM AND CARDIAC MAGNETIC RESONANCE IMAGING IN ACUTE MYOCARDITIS
- PO 360 AUTOMATIC PARAMETER OBTAINED BY ARTIFICIAL INTELLIGENCE IN CMR FOR THE ASSESSMENT OF LEFT VENTRICULAR FUNCTION IN PATIENTS WITH DILATED AND HYPERTROPHIC CARDIOMYOPATHY

B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING

- PO 70 CAN SYSTEMIC IMMUNE INFLAMMATORY INDEX BEAT 18F-FDG PET-CT IN IDENTIFYING BREAST CANCER PATIENTS WITH INCREASED RISK OF VASCULAR DISEASE?
- PO 96 PHASE ANALYSIS OF SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY MYOCARDIAL PERFUSION IMAGING (SPECT-MPI): CLOSER TO THE ROOT OF LEFT BUNDLE BRANCH BLOCK CARDIOMYOPATHY?

B. IMAGING -> 03. IMAGING -> 03.6 CROSS-MODALITY AND MULTI-MODALITY IMAGING TOPICS

- PO 374 LV REVERSE REMODELING AFTER SAVR IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC STENOSIS: IMPACT ON THE CLINICAL OUTCOME

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.2 ARRHYTHMIAS, GENERAL - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 13 LEFT ATRIAL VOLUME PREDICTS MAJOR ADVERSE CARDIAC EVENTS AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.3 ARRHYTHMIAS, GENERAL - DIAGNOSTIC METHODS

- PO 122 AJMALINE TESTING IN BRUGADA SYNDROME: A COMPARATIVE ANALYSIS OF DIAGNOSTIC PROTOCOLS AND CLINICAL OUTCOMES ACROSS TWO HOSPITALS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.6 ARRHYTHMIAS, GENERAL - CLINICAL

- PO 100 24H-HOLTER MONITORING IN MYOTONIC DYSTROPHY TYPE 1 FOLLOW-UP: IS IT REALLY NEEDED?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.1 ATRIAL FIBRILLATION - PATHOPHYSIOLOGY AND MECHANISMS

- PO 204 DECODING THE COMPLEXITY OF ATRIAL FIBRILLATION: UNVEILING DISTINCT PHENOTYPES OF VOLTAGE AND CONDUCTION VELOCITY

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 205 ELECTRICAL CARIOVERSION AND ATRIAL FIBRILLATION RECURRENCE: THE PROGNOSTIC VALUE OF P WAVE ANALYSIS
- PO 206 THE NOWADAYS IMPACT OF THE PRESENCE OF ATRIAL FIBRILLATION IN THE PROGNOSIS OF PATIENTS WITH ACUTE CORONARY SYNDROME

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.3 ATRIAL FIBRILLATION - DIAGNOSTIC METHODS

- PO 207 USE OF SMARTWATCHES FOR ATRIAL FIBRILLATION DETECTION: A SYSTEMATIC REVIEW.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT

- CO 51 SAFETY AND EFFECTIVENESS OF PULSED FIELD ABLATION FOR PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION PATIENTS: A SINGLE CENTRE EXPERIENCE
- CO 52 PULSED FIELD ABLATION: A NEW ERA IN ATRIAL FIBRILLATION TREATMENT?
- CO 53 ANATOMIC-GUIDED ABLATION OF THE RIGHT GANGLIONATED PLEXI VALIDATED BY THE AUTOMATIC FRACTIONATION MAP
- CO 85 LEFT ATRIAL WALL THICKNESS MEASURED BY A MACHINE LEARNING METHOD PREDICTS AF RECURRENCE AFTER PULMONARY VEIN ISOLATION
- PO 82 SAME-DAY DISCHARGE AFTER ATRIAL FIBRILLATION ABLATION: IS IT SAFE?
- PO 83 PULMONARY VEINS ANATOMY VARIANTS AND CRYOBALLOON ABLATION FOR ATRIAL FIBRILLATION
- PO 84 EARLY EXPERIENCE WITH A NEW MULTI-ELECTRODE RADIOFREQUENCY BALLOON USING INTEGRATED 3D IMAGING FOR PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION
- PO 85 CHARACTERIZING RECURRENT ATRIAL FIBRILLATION AFTER CATHETER ABLATION: PATTERNS OF PULMONARY VEIN RECONNECTION AND PREDICTORS OF COMPLETE PULMONARY VEIN ISOLATION
- PO 86 ROLE OF COMBINED PULMONARY VEIN ISOLATION WITH LEFT ATRIAL GANGLIONATED PLEXUS ABLATION IN PAROXYSMAL ATRIAL FIBRILLATION AND SINUS BRADYCARDIA
- PO 87 ECHOCARDIOGRAPHIC FACTORS IN SHORT TERM RECURRENCE AFTER ATRIAL FIBRILLATION ABLATION
- PO 208 BIOPHYSICAL PARAMETERS OF PULMONARY VEIN ISOLATION WITH VERY HIGH-POWER SHORT-DURATION COMPARED TO CONVENTIONAL RADIOFREQUENCY ABLATION GUIDED BY ABLATION INDEX.
- PO 209 POSTERIOR WALL ISOLATION IN PERSISTENT ATRIAL FIBRILLATION: PULSED-FIELD ABLATION VS. RADIOFREQUENCY
- PO 377 INCIDENCE OF ATRIAL FIBRILLATION DURING THE FIRST WEEK OF BLANKING PERIOD: PULSED-FIELD ABLATION VS HIGH-POWER SHORT-DURATION RADIOFREQUENCY ABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.5 ATRIAL FIBRILLATION - STROKE PREVENTION

- CO 82 LEFT ATRIAL STIFFNESS AS A PREDICTOR OF SUBCLINICAL ATRIAL FIBRILLATION AND A MARKER OF STROKE RECURRENCE IN A COHORT OF PATIENTS WITH CRYPTOGENIC STROKE
- PO 15 IMPROVING ADHERENCE TO ANTICOAGULATION: A NUDGE STRATEGY-BASED INTERVENTION ON PATIENTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER SCHEDULED FOR ELECTRICAL CARIOVERSION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.1 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - PATHOPHYSIOLOGY AND MECHANISMS

- PO 264 ATYPICAL RIGHT ATRIUM FLUTTERS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.2 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 265 EVALUATION OF THE USE OF OPEN WINDOW MAPPING WITH HIGH DENSITY CATERER IN PATIENTS WITH WOLFF-PARKINSON-WHITE IN A TERTIARY CARE UNIT

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.4 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - TREATMENT

PO 266 RADIOFREQUENCY CATHETER ABLATION OF ANTEROSEPTAL AND MIDSEPTAL ACCESSORY PATHWAYS IN THE ERA OF ELECTROANATOMIC MAPPING SYSTEMS AND IRRIGATED CATHETERS

PO 267 BIATRIAL FLUTTERS UNCOMMON CIRCUITS REQUIRING TAILORED ABLATION APPROACH

PO 268 INITIAL EXPERIENCE WITH A NOVEL TEMPERATURE-CONTROLLED RADIOFREQUENCY CATHETER ABLATION FOR THE TREATMENT OF ATRIAL FLUTTER

PO 269 ACCESSORY PATHWAY ABLATION IN WOLFF-PARKINSON-WHITE SYNDROME: A DECADE OF EXPERIENCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.3 SYNCOPE AND BRADYCARDIA - DIAGNOSTIC METHODS

PO 277 SYMPTOM-RHYTHM CORRELATION OF IMPLANTABLE LOOP RECORDERS IN PATIENTS WITH SYNCOPE/PRESYNCOPE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT

CO 21 THE ROLE OF CARDIONEUROABLATION FOR THE TREATMENT OF HEART RHYTHM DISORDERS

CO 25 CARDIONEUROABLATION USING EXTRACARDIAC VAGAL STIMULATION: A PROMISING ALTERNATIVE TO PACEMAKER THERAPY IN CARDIOINHIBITORY VASOVAGAL SYNCOPE

CO 78 LEADLESS PACING SYSTEM: REAL-WORD COMPARISON BETWEEN TWO SYSTEM DEVICES

PO 278 LONG-TERM RESULTS OF CARDIONEUROABLATION EVALUATED BY IMPLANTABLE LOOP RECORDER

PO 280 UNRAVELING THE STORY OF HUNDREDS OF SYNCOPEs AND PRE-SYNCOPEs

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.1 VENTRICULAR ARRHYTHMIAS AND SCD - PATHOPHYSIOLOGY AND MECHANISMS

PO 177 CONTRIBUTES OF GENETIC TESTING TO UNDERSTANDING THE AETIOLOGY OF SUDDEN CARDIAC ARREST: 4-YEAR EXPERIENCE OF GENETIC LABORATORY

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.2 VENTRICULAR ARRHYTHMIAS AND SCD - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 178 UTILITY OF RESTING ELECTROCARDIOGRAM IN SCREENING AND RISK STRATIFICATION OF BRUGADA SYNDROME

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.3 VENTRICULAR ARRHYTHMIAS AND SCD - DIAGNOSTIC METHODS

CO 23 ELECTROCARDIOGRAPHIC IMAGING TO GUIDE ABLATION OF VENTRICULAR ARRHYTHMIAS SHOWS A HIGHER BENEFIT IN PATIENTS WITH LOW INTRAPROCEDURAL BURDEN

CO 97 LONG TERM PROGNOSIS OF IDIOPATHIC VENTRICULAR ARRHYTHMIAS: AN EIGHTEEN-YEAR EXPERIENCE FROM A TERTIARY CENTER

- PO 182 ROLE OF PROGRAMMED VENTRICULAR STIMULATION IN RISK STRATIFICATION OF TYPE 1 ASYMPTOMATIC BRUGADA PATIENTS
- PO 184 USEFULNESS OF SUBCUTANEOUS IMPLANTABLE LOOP RECORDER IN BRUGADA SYNDROME: A SINGLE CENTER EXPERIENCE.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT

- CO 24 NEUROMODULATION IN ELECTRICAL STORM: SAFETY AND EFFICACY OF RENAL DENERVATION
- CO 99 LONG-TERM OUTCOMES OF VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY: A PROPENSITY-SCORE MATCHED ANALYSIS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.5 VENTRICULAR ARRHYTHMIAS AND SCD - PREVENTION

- CO 88 REVISITING RISK STRATIFICATION IN HYPERTROPHIC CARDIOMYOPATHY AFTER RECENT GUIDELINES - LATE GADOLINIUM ENHANCEMENT REMAINS TOUGH TO BEAT
- PO 179 SHANGAI SCORE AS AN OUTCOME PREDICTOR FOR BRUGADA SYNDROME PATIENTS
- PO 181 PROGNOSTIC VALUE OF PROGRAMMED ELECTRICAL STIMULATION IN BRUGADA SYNDROME: A SINGLE-CENTER STUDY.
- PO 183 PROGNOSTIC SIGNIFICANCE OF PROGRAMMED VENTRICULAR STIMULATION IN BRUGADA PATIENTS
- PO 185 PREDICTORS OF IMPLANTABLE CARDIO-DEFIBRILLATOR ACTIVATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AT PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING

- CO 76 LEFT BUNDLE BRANCH AREA PACING: THE INITIAL EXPERIENCE AT A PORTUGUESE TERTIARY CENTER
- CO 77 FROM RIGHT TO LEFT: LEFT BUNDLE BRANCH AREA PACING VS CONVENTIONAL RIGHT VENTRICULAR PACING
- CO 80 INITIAL EXPERIENCE AND MEDIUM-TERM RESULTS OF LEFT BUNDLE BRANCH AREA PACING
- PO 276 LEFT BUNDLE BRANCH AREA PACING USING STYLET-DRIVEN PACING LEADS- EXPERIENCE OF ONE CENTER
- PO 281 MID-TERM VENTRICULAR PACING PERCENTAGE IN PATIENTS REQUIRING PACEMAKER IMPLANTATION FOLLOWING TAVR: INSIGHTS FROM A LARGE SINGLE-CENTER EXPERIENCE
- PO 282 LEFT BUNDLE BRANCH AREA PACING IN TAVI PATIENTS: A FEASIBLE ALTERNATIVE?
- PO 283 THE LEARNING CURVE OF LEFT BUNDLE BRANCH AREA PACING: FEASIBILITY, SAFETY AND ACUTE SUCCESS RATES - A SINGLE-CENTER EXPERIENCE
- PO 284 LEADLESS PACEMAKER - LEAD PARAMETERS STABILITY AND BATTERY LONGEVITY IN THE MID-TERM FOLLOW-UP

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARDIOVERTER / DEFIBRILLATOR

- CO 36 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN HEART FAILURE WITH REDUCED EJECTION FRACTION: EVALUATING EFFICACY IN THE ERA OF CONTEMPORARY PHARMACOTHERAPY
- PO 180 EFFECT OF SGLT2 INHIBITORS IN SUSTAINED VENTRICULAR TACHYARRHYTHMIAS IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS FOR PRIMARY PREVENTION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY

- CO 79 META-ANALYSIS COMPARING CARDIAC RESYNCHRONIZATION THERAPY WITH OR WITHOUT DEFIBRILLATION IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY

- PO 195 IMPACT OF RIGHT VENTRICULAR DIMENSION AND FUNCTION ON OUTCOMES IN PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
- PO 196 LEFT BUNDLE BRANCH AREA PACING: A PARADIGM SHIFT IN CARDIAC RESYNCHRONIZATION THERAPY
- PO 197 CLINICAL EFFICIENCY AND DURABILITY OF THE EPICARDIAL LEFT VENTRICULAR LEADS IN CARDIAC RESYNCHRONIZATION THERAPY.
- PO 198 PREDICTORS OF NON-RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY
- PO 199 ALIGNING HUMAN AND MACHINE - PREDICTORS OF SUPER-RESPONSE TO CRT
- PO 200 IMPROVEMENT OF FUNCTIONAL MITRAL REGURGITATION FOLLOWING CARDIAC RESYNCHRONIZATION THERAPY: PREDICTORS AND CLINICAL OUTCOMES
- PO 201 IMPACT OF ATRIAL FIBRILLATION ON MORTALITY AND RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE: A RETROSPECTIVE ANALYSIS
- PO 202 FROM REDUCED TO NORMAL LEFT VENTRICULAR EJECTION FRACTION: WHAT MAKES A SUPER-RESPONDER TO CRT?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.4 HOME AND REMOTE PATIENT MONITORING

- PO 101 CYBERNETIC GUARDIANS: REVOLUTIONIZING CARDIAC CARE THROUGH REMOTE MONITORING OF IMPLANTABLE DEVICES
- PO 102 PROGNOSTIC IMPACT OF MAXIMAL NOCTURNAL HEART RATE IN HEART FAILURE PATIENTS WITH AN IMPLANTABLE ELECTRONIC DEVICE.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.5 DEVICE COMPLICATIONS AND LEAD EXTRACTION

- CO 94 LEAD EXTRACTIONS IN A SINGLE CENTER: A RECTROSPECTIVE ANALYSIS OVER THE LAST 26 YEARS
- PO 103 PROLONGED ANTIBIOTIC THERAPY BEFORE LEAD EXTRACTION IN CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTIONS AS A WAY FOR DIMINISHING THE RATE OF SEPTIC SHOCK.
- PO 104 INCIDENTAL NON-INFECTIOUS MASSES ON CARDIAC IMPLANTABLE ELECTRONIC DEVICE LEADS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.6 DEVICE THERAPY - OTHER

- PO 105 EARLY DISCHARGE FOLLOWING CARDIAC IMPLANTABLE ELECTRONIC DEVICE IMPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 223 ECG IMAGING FOR REAL-TIME ASSESSMENT OF VENTRICULAR SYNCHRONY IN PHYSIOLOGICAL PACING
- PO 279 LONG-TERM IMPACT OF PACEMAKER IMPLANTATION AFTER TAVI: A SUBGROUP ANALYSIS ACCORDING TO PREVIOUS INTRAVENTRICULAR CONDUCTION DISTURBANCES

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.1 CHRONIC HEART FAILURE - PATHOPHYSIOLOGY AND MECHANISMS

- PO 112 HEART FAILURE AND CHRONIC KIDNEY DISEASE: CHLORIDE AND MARKERS OF FLUID OVERLOAD AND DIURETIC RESISTANCE
- PO 216 CORRELATING CARDIOPULMONARY EXERCISE TESTING AND RIGHT HEART CATHETERIZATION PARAMETERS IN ADVANCED HEART FAILURE: INSIGHTS FOR PATIENT EVALUATION

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- CO 37 PROGNOSTIC IMPACT OF RESIDUAL CONGESTION ESTIMATED BY BIOIMPEDANCE IN HEART FAILURE
- CO 83 UROCORTIN-2 AS A NOVEL BIOMARKER OF CLINICAL DETERIORATION IN HFPEF: A PROSPECTIVE COHORT STUDY

- PO 113 NTPROBNP IS NOT A GOOD PROGNOSTIC MARKER IN PATIENTS WITH ADVANCED HEART FAILURE ON AMBULATORY LEVOSIMENDAN INFUSION PROGRAM
- PO 115 PREDICTING HEART FAILURE OUTCOMES WITH A NEW MALNUTRITION AND INFLAMMATION SEVERITY INDEX - MISI SCORE
- PO 116 PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH HEART FAILURE - INSIGHTS FROM A REAL-WORLD POPULATION FOLLOWED IN A REGIONAL HOSPITAL
- PO 117 PREDICTION OF INDIVIDUAL LIFETIME RISK IN PORTUGUESE PATIENTS WITH HFREF
- PO 217 O₂ CONSUMPTION OVERSHOOT IN PATIENTS WITH HEART FAILURE: CROSSING THE LINE
- PO 220 EXERCISE STRESS TESTING RECOVERY KINETICS: THE FORGOTTEN PHASE
- PO 232 MID-RANGE EJECTION FRACTION AFTER STEMI: DIFFERENT APPLES IN THE SAME BASKET
- PO 244 BEYOND ASSUMPTIONS: NT-PROBNP RISE AND DIURETIC STRATEGIES IN HFREF THERAPY UP-TITRATION
- PO 247 INTERMITTENT LEVOSIMENDAN CYCLES: A SINGLECENTRE CLINICAL EXPERIENCE
- PO 248 SLIDING DOWN A SLOPE - THE PROGNOSTIC VALUE OF DIFFERENT METHODS OF MEASURING VE/VCO₂ IN HEART FAILURE
- PO 249 "I NEED HELP": UNLEASHING THE FULL POTENTIAL OF THE ACRONYM FOR THE MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
- PO 257 THE CLINICAL VALUE OF BIOELECTRICAL PHASE ANGLE IN HEART FAILURE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS

- PO 218 LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN IS ASSOCIATED WITH INVASIVE FILLING PRESSURES AND CARDIAC OUTPUT IN THE AMBULATORY SETTING: INSIGHTS FROM THE CARDIOMEMS™
- PO 219 UNVEILING THE INTERPLAY OF PULMONARY HYPERTENSION PARAMETERS FROM RIGHT HEART CATHETERIZATION WITH CARDIOPULMONARY EXERCISE TESTING IN HEART FAILURE PATIENTS
- PO 246 ASSESSMENT OF SUBCLINICAL HYPERVOLEMIA BY BIOIMPEDANCE SPECTROSCOPY IN HEART FAILURE
- PO 258 PREVALENCE OF ECHOCARDIOGRAPHIC FINDINGS COMPATIBLE WITH PRESERVED EJECTION FRACTION HEART FAILURE IN A REAL-WORLD PRACTICE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT

- CO 16 EFFECTIVENESS OF A CARDIAC REHABILITATION PROGRAM IN PATIENTS WITH HEART FAILURE AND SKELETAL MUSCLE WEAKNESS
- CO 38 HEARTMATE 3™ EXPERIENCE: A SINGLE-CENTER RETROSPECTIVE STUDY
- CO 39 OPTIMAL TIMING OF CRT IMPLANTATION IN HEART FAILURE - A COMPARATIVE ANALYSIS OF LVEF RECOVERY AND DEVICE IMPLANTATION
- CO 75 DAPAGLIFLOZIN'S INFLUENCE ON CARDIAC REMODELING IN CHRONIC HEART FAILURE PATIENTS
- PO 155 LEFT EJECTION FRACTION FOLLOWING CHRONIC TOTAL CORONARY OCCLUSION RECANALIZATION - APPROPRIATE PATIENT SELECTION NEEDED?
- PO 203 MITRAL REGURGITATION IN HEART FAILURE PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY - DOES IT AFFECTS CLINICAL OUTCOMES?
- PO 240 REAL-WORLD IMPACT OF EARLY QUADRUPLE THERAPY IN HFREF: A COMPARATIVE ANALYSIS OF SEQUENTIAL VS. SIMULTANEOUS APPROACHES
- PO 242 QUADRUPLE THERAPY AT DISCHARGE: ENHANCING CLINICAL TRAJECTORIES IN DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 243 REAL-WORLD DAPAGLIFLOZIN AND CONCOMITANT MEDICATION TREATMENT PATTERNS IN PORTUGUESE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 245 VERICIGUAT ELIGIBILITY IN HEART FAILURE: EARLY POST-DISCHARGE ASSESSMENT
- PO 250 HOME ADMINISTRATION OF LEVOSIMENDAN IN PATIENTS WITH ADVANCED HEART FAILURE - THE LEVO-HOME PILOT PROJECT

- PO 251 INTERMITTENT OUTPATIENT ADMINISTRATION OF LEVOSIMENDAN IN PATIENTS WITH ADVANCED HEART FAILURE: IS IT ENOUGH?
- PO 252 AGE-RELATED IMPLICATIONS IN GUIDELINE-DIRECTED MEDICAL THERAPY UP-TITRATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: A RETROSPECTIVE SINGLE-CENTER STUDY
- PO 253 BEYOND 3 MONTHS: UNRAVELING THE PROLONGED IMPACT OF OPTIMIZED MEDICAL THERAPY ON LVEF AND ICD IMPLANTATION IN HFREF PATIENTS
- PO 256 THE EFFECT OF INTRAVENOUS IRON-CARBOHYDRATE COMPLEXES ON QUALITY OF LIFE IN PATIENTS WITH ACUTE VS CHRONIC HEART FAILURE - A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 259 PREDICTION OF WAIT TIMES IN HEART TRANSPLANTATION IN PORTUGAL
- PO 260 CLINICAL OUTCOMES OF IMPLANTABLE CARIOVERTER DEFIBRILLATORS IN HEART FAILURE: A COMPARATIVE ANALYSIS BETWEEN ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY PATIENTS
- PO 261 ASSOCIATION BETWEEN IMPAIRED KIDNEY FUNCTION AND WORSE RESPONSE TO LEVOSIMENDAN TREATMENT
- PO 375 MAY ORAL IRON PLAY A ROLE IN HFREF WITH IRON DEFICIENCY? A SECONDARY ANALYSIS OF IRONOUT HF RANDOMIZED CONTROLLED TRIAL

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.5 CHRONIC HEART FAILURE - PREVENTION

- PO 263 IMPACT OF ACTIVE INTERVENTION IN HIGH-RISK HEART FAILURE PATIENTS UNDER A TEAM-BASED REMOTE MONITORING UNIT

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL

- CO 40 HOME INTRAVENOUS DIURETICS: A WAY TO REDUCE HOSPITAL BED USAGE AND URGENT ADMISSIONS
- PO 114 PHENOTYPING HEART FAILURE PATIENTS WITH SUBCLINICAL CONGESTION
- PO 221 BEYOND BEATS: AN ANALYSIS OF HEMODYNAMICS AND EXERCISE CAPACITY IN HEART FAILURE PATIENTS WITH ATRIAL FIBRILLATION
- PO 241 HEART FAILURE ETIOLOGY AND ARNI+SGLT2I INITIATION MAY INFLUENCE ICD IMPLANTATION TIMING
- PO 254 ASSOCIATION BETWEEN PHYSICIAN-PERCEIVED FUNCTIONAL CLASS AND FUNCTIONAL CAPACITY MEASURED BY EXERCISE STRESS TEST IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER

- PO 262 TWO YEARS OF ACTIVITY AT A HEART FAILURE DAY HOSPITAL IN A PRIVATE HOSPITAL: A REAL-WORLD PORTRAIT

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 132 EARLY POST-DISCHARGE NTPROBNP LEVELS AS A MARKER OF PROGNOSIS IN HEART FAILURE PATIENTS
- PO 133 UREA LEVELS AT ADMISSION: A FORGOTTEN YET CRUCIAL PROGNOSTIC MARKER IN HOSPITALIZED HEART FAILURE PATIENTS

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.4 ACUTE HEART FAILURE- TREATMENT

- PO 134 HIGH-FLOW NASAL CANNULA VERSUS CONVENTIONAL OXYGEN THERAPY IN ACUTE HEART FAILURE: A META-ANALYSIS
- PO 135 PERFORMANCE OF FENNIX SCORE IN POST-DISCHARGE HEART FAILURE APPOINTMENT: A PREDICTOR OF FUTURE HOSPITALIZATION
- PO 136 ACETAZOLAMIDE EFFICACY AND SAFETY IN PATIENTS WITH ACUTE HEART FAILURE WITH VOLUME OVERLOAD: A SYSTEMATIC REVIEW AND META-ANALYSIS.
- PO 140 PATIROMER AS A CORNERSTONE FOR HYPERKALEMIA MANAGEMENT IN SPIRONOLACTONE-UNTREATED PATIENTS - A REAL-WORLD PERSPECTIVE

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.5 ACUTE HEART FAILURE- PREVENTION

PO 255 REMOTE MONITORING OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES FOR PREDICTING ACUTE CLINICAL DECOMPENSATION EVENTS IN HEART FAILURE PATIENTS

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.6 ACUTE HEART FAILURE - CLINICAL

PO 137 WHAT DOES THE RATIO UREA-TO-CREATININE IN HEART FAILURE HOSPITALIZATIONS TELL US?

PO 138 REAL-WORLD APPLICABILITY OF THE EMERGENCY HEART FAILURE MORTALITY RISK GRADE IN REDUCING HOSPITALIZATION

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.7 ACUTE HEART FAILURE - OTHER

PO 139 BEYOND NT-PROBNP: CA-125'S DISTINCTIVE ROLE IN HEART FAILURE - INSIGHTS INTO RIGHT VENTRICULAR PREDOMINANCE AND TRICUSPID REGURGITATION

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.1 CORONARY ARTERY DISEASE - PATHOPHYSIOLOGY AND MECHANISMS

CO 31 DOES THE LPA GENOTYPE HAVE A ROLE IN CORONARY ARTERY DISEASE RISK BEYOND LIPOPROTEIN(A) VALUES?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.2 CORONARY ARTERY DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 124 IMPACT OF CANCER HISTORY ON NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (NSTEMI) PROGNOSIS - A PROPENSITY-SCORE MATCHING (PSM) ANALYSIS

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC METHODS

CO 29 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY BEFORE INVASIVE CORONARY ANGIOGRAPHY IN CABG PATIENTS

CO 43 CLINICAL VERSUS ALGORITHMIC PREDICTION OF OBSTRUCTIVE CORONARY ARTERY DISEASE - THE CASINO STUDY

CO 96 NON-INVASIVE DERIVATION OF IFR FROM INVASIVE CORONARY ANGIOGRAPHY USING A NEW DEEP LEARNING AI MODEL AND COMPARISON WITH HUMAN OPERATORS' PERFORMANCE

PO 125 EVALUATION OF DIAGNOSTIC ACCURACY OF THE MODIFIED CHA2DS2-VASC SCORE IN PREDICTING OBSTRUCTIVE CORONARY DISEASE AMONG PATIENTS SUSPECTED OF CHRONIC CORONARY SYNDROME

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.4 CORONARY ARTERY DISEASE - TREATMENT

PO 187 INTRAVASCULAR LITHOTRIPSY EFFECTIVENESS AND SAFETY IN A LARGE REAL-WORLD COHORT

PO 189 AMBULATORY PCI ANALYSIS - INSIGHTS FROM SINGLE CENTER EXPERIENCE

PO 191 LONG-TERM OUTCOMES OF A DEDICATED CHRONIC TOTAL OCCLUSION - PERCUTANEOUS CORONARY INTERVENTION (CTO-PCI) PROGRAM

PO 192 SAME DAY DISCHARGE FOR PERCUTANEOUS CORONARY INTERVENTION - A 4-YEAR SINGLE-CENTER EXPERIENCE

PO 273 A DECADE OF URGENT AND EMERGENT UNPROTECTED LEFT MAIN STEM PERCUTANEOUS CORONARY INTERVENTION: OUTCOMES FROM A PORTUGUESE CARDIAC CENTER

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.8 CORONARY ARTERY DISEASE - OTHER**

PO 193 LONG AND MIXT/NON-CALCIFIED PLAQUES AS PREDICTORS OF FUNCTIONALLY SIGNIFICANT CORONARY ARETRY DISEASE

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.1 ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGY AND MECHANISMS**

CO 32 IS GENETIC INFORMATION HELPFUL IN PREDICTING RECURRENT EVENTS IN YOUNG PATIENTS AFTER ACUTE CORONARY SYNDROME?

PO 130 GENE-GENE AND GENE-ENVIRONMENT INTERACTION IN CORONARY ARTERY DISEASE RISK

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

CO 42 SEX DISPARITIES IN MID-TERM OUTCOMES OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION ACROSS AGE

PO 123 PROGNOSTIC IMPACT OF COMPLETE REVASCULARIZATION DURING INDEX HOSPITALIZATION FOR NON-ST ELEVATION MYOCARDIAL INFARCTION

PO 126 MODERATE TO SEVERE CHRONIC KIDNEY DISEASE AND ACUTE CORONARY SYNDROMES - APPROACH AND OUTCOMES

PO 129 LIPOPROTEIN (A): WHAT ROLE IN LONG-TERM PROGNOSIS OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

PO 131 PROGNOSTIC IMPACT OF ESTIMATED GLOMERULAR FILTRATION RATE IN PATIENTS WITH ACUTE CORONARY SYNDROME - WHICH IS THE BEST FORMULA?

PO 158 REVASCULARIZATION STRATEGIES IN ELDERLY PATIENTS WITH MULTIVESSEL DISEASE: A COMPARATIVE ANALYSIS OF COMPLETE AND INCOMPLETE INTERVENTIONS

PO 211 THE PORTUGUESE MINOCA PATIENTS: INSIGHTS FROM A MULTICENTRE NATIONAL REGISTRY ANALYSIS

PO 233 GENDER DIFFERENCE IN REFERRAL PATHWAY IN PRIMARY PCI

PO 270 LEFT MAIN PERCUTANEOUS INTERVENTION FOR MYOCARDIAL INFARCTION: A TERTIARY CENTRE RETROSPECTIVE STUDY

PO 328 DEMOGRAPHIC AND ANGIOGRAPHIC CHARACTERISTICS IN PREMATURE CASES OF ACUTE CORONARY SYNDROME

PO 329 ACUTE CORONARY SYNDROMES: MEN AND WOMEN - SAME SPECIES, SAME DISEASE, SAME MANIFESTATION?

PO 330 IS THE CARDIOPROTECTIVE EFFECT OF PRE-INFARCTION ANGINA BLUNTED BY AGE?

PO 331 GENDER DIFFERENCES IN OUTCOMES FOLLOWING ACUTE CORONARY SYNDROME IN YOUNG ADULTS

PO 332 IMPACT OF ACUTE CULPRIT OCCLUSION IN PATIENTS PRESENTING WITH NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS**

PO 127 RISK STRATIFICATION OF CHEST PAIN IN A PORTUGUESE EMERGENCY DEPARTMENT: IS THE HEART SCORE APPROPRIATE?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT**

CO 41 PRE-TREATMENT WITH UNFRACTIONATED HEPARIN ALONGSIDE ASPIRIN AND A P2Y12 INHIBITOR IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

CO 44 OPTIMIZING COMPLETE REVASCULARIZATION STRATEGY IN STEMI: INSIGHTS FROM A REAL-WORLD SINGLE-CENTER ANALYSIS

- CO 45 CORONARY ARTERY ANEURISMS PRESENTING AS ACUTE CORONARY SYNDROME - ANTICOAGULATION THERAPY OR ANTIPLATELET THERAPY ALONE?
- CO 69 VENOARTERIAL EXTRACORPOREAL MEMBRANE OXIGENATION FOR INFARCT RELATED CARDIOGENIC SHOCK: A REAL-WORLD COMPARISON OF PATIENT CANDIDATES, PRACTICES AND OUTCOMES
- PO 61 A GLOBAL PERSPECTIVE ON LIPID CONTROL AFTER ACUTE CORONARY SYNDROME - ARE WE DOING ENOUGH?
- PO 63 REAL-LIFE IMPACT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AFTER ACUTE CORONARY SYNDROME
- PO 190 PERCUTANEOUS TREATMENT OF SAPHENOUS VEIN GRAFTS- A REAL LIFE ANALYSIS
- PO 228 MANUAL THROMBUS ASPIRATION - 12-YEAR SINGLE CENTRE EXPERIENCE
- PO 230 LONG TERM BETA-BLOCKERS AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PATIENTS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
- PO 234 PROGNOSTIC IMPLICATIONS OF P2Y12 INHIBITOR PRETREATMENT IN NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES UNDERGOING LATE INVASIVE STRATEGY - A NATIONAL REGISTRY ANALYSIS
- PO 235 EFFICACY AND SAFETY OF USING 3 VS 12-MONTH ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION: META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS
- PO 236 PRECISE DAPT SCORE FOR PREDICTION OF OUTCOMES IN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION FOR PROXIMAL LEFT ANTERIOR DESCENDING ARTERY.
- PO 237 TRIPLE ANTITHROMBOTIC THERAPY IN ACUTE CORONARY SYNDROME IN PATIENTS WITH MODERATE-HIGH ISCHEMIC RISK: HOW TO DEFINE THE DURATION OF TREATMENT TAKING INTO ACCOUNT THE OUTCOME?
- PO 239 STEMI DUAL ANTIPLATELET PRETREATMENT - PORTUGUESE MULTICENTER EXPERIENCE
- PO 271 PERCUTANEOUS REVASCLARIZATION OF LEFT MAIN CORONARY ARTERY IN DIABETIC PATIENTS
- PO 274 LEFT MAIN CORONARY ARTERY ANGIOPLASTY IN PATIENTS WITH NON-COMPLEX CORONARY ARTERY DISEASE
- PO 333 CORONARY ANGIOGRAPHY IN HIGH-RISK NON-ST-ELEVATION ACUTE CORONARY SYNDROME - THE SOONER THE BETTER?
- PO 334 ARE WE GENDER-BIASED IN PRESCRIPTION PRACTICES? AN ANALYSIS OF THE PORTUGUESE REGISTRY OF ACUTE CORONARY SYNDROMES
- PO 335 COMPARATIVE SAFETY AND EFFICACY OF ROTATIONAL ATHERECTOMY IN NSTE-ACS AND SA PATIENTS: A RETROSPECTIVE STUDY
- PO 336 REVASCLARIZATION STRATEGIES IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROMES AND MULTIVESSEL DISEASE: A COMPARATIVE ANALYSIS OF CULPRIT-ONLY VS. COMPLETE REVASCLARIZATION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.7 ACUTE CORONARY SYNDROMES - OTHER**

- PO 229 PRIMARY PCI IN A REGIONAL CENTRE - 7 YEARS OF CHANGE AND IMPROVEMENT
- PO 231 PRIMARY PCI IN A REGIONAL CENTRE - PANDEMIC IMPACT
- PO 238 DEVELOPMENT OF A CLINICAL RISK SCORE FOR EARLY LEFT VENTRICULAR THROMBUS PREDICTION FOLLOWING ANTERIOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
- PO 327 SEX DIFFERENCES IN ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND PRESERVED EJECTION FRACTION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL CARDIOVASCULAR CARE**

- CO 66 CARDIOGENIC SHOCK MANAGEMENT WITH VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION: A SINGLE-CENTER ANALYSIS
- CO 67 INTRA-AORTIC BALLOON PUMP PLACEMENT AT THE BEDSIDE: A SINGLE-CENTER EXPERIENCE OF CICU VERSUS CATHLAB INSERTION, MANAGEMENT, AND REMOVAL.
- CO 68 DIASTOLIC SHOCK INDEX: A NOVEL PROGNOSTIC PARAMETER UNVEILING INSIGHTS INTO VASODILATORY CARDIOGENIC SHOCK

- PO 128 EXPLORING THE SIGNIFICANCE OF PROCALCITONIN IN CARDIOGENIC SHOCK FOR THE PREDICTION OF INFECTION AND MORTALITY OUTCOMES
- PO 212 COEXISTENCE AND PROGNOSTIC IMPACT OF CORONARY ARTERY DISEASE IN TAKOTSUBO SYNDROME
- PO 215 CAN WE PREDICT IN-HOSPITAL COMPLICATIONS IN TAKOTSUBO SYNDROME?
- PO 314 ECMO-RELATED VASCULAR COMPLICATIONS: A SINGLE-CENTER EXPERIENCE IN A PORTUGUESE TERTIARY HOSPITAL

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK**

- CO 1 PULMONARY ARTERY CATHETERIZATION IN CARDIOGENIC SHOCK - A PROPENSITY MATCHED ANALYSIS ON MANAGEMENT AND PROGNOSTIC IMPACT
- CO 2 LEFT VENTRICLE UNLOADING TECHNIQUES IN VA-ECMO: A COMPARATIVE ANALYSIS IN CARDIOGENIC SHOCK PATIENTS
- CO 3 VASODILATORY CARDIOGENIC SHOCK: EPIDEMIOLOGY, INVASIVE PHENOTYPING AND PROGNOSTIC IMPLICATIONS.
- CO 4 DECODING CARDIOGENIC SHOCK COMPLEXITY: VALIDATION AND PROGNOSTIC SIGNIFICANCE OF MACHINE-LEARNING PHENOTYPES IN A PORTUGUESE PATIENT COHORT
- PO 19 UNVEILING MORTALITY OUTCOMES IN CARDIOGENIC SHOCK ADULT PATIENTS WITH PERIPHERAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXIGENATION
- PO 20 IABP IMPLANTATION TRENDS AFTER THE TRIALS - WHEN IT GETS CRITICAL, DO WE FOLLOW GUIDELINES?
- PO 21 REAL-WORLD INSIGHTS: PRACTICAL IMPELLA OUTCOMES IN CARDIOGENIC SHOCK AND HIGH-RISK ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
- PO 22 VASCULAR COMPLICATIONS OF INTRA-AORTIC BALLOON PUMP (IABP) IMPLANTATION - A SINGLE-CENTER ANALYSIS.
- PO 23 CARDIOGENIC SHOCK FOLLOWING ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN WOMEN: COMPLICATIONS AND OUTCOMES.
- PO 373 PRECISION IN PROGNOSTICATION: A COMPREHENSIVE COMPARISON OF RISK SCORES IN THE SETTING OF CARDIOGENIC SHOCK

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.5 ACUTE CARDIAC CARE - CARDIAC ARREST**

- PO 24 CALCIUM HIDES THE CLUE: UNRAVELING THE DIAGNOSTIC VALUE OF EARLY CORONARY CALCIUM SCORING IN CARDIAC ARREST SURVIVORS
- PO 25 OUT-OF-HOSPITAL CARDIAC ARREST: EPIDEMIOLOGY, ICU OUTCOMES, AND PROGNOSTIC INSIGHTS
- PO 26 BEYOND THE ARREST: ASSESSING SURVIVAL WITH SOFA AND SAPS II SCORES IN OHCA PATIENTS
- PO 27 SURVIVAL CLOCK: UNVEILING MORTALITY PREDICTORS IN OUT-OF-HOSPITAL CARDIAC ARREST

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
14. ACUTE CARDIAC CARE -> 14.6 ACUTE CARDIAC CARE - OTHER**

- CO 62 KASH SCORE - A CLINICAL SCORE TO PREDICT IN-HOSPITAL MORTALITY IN TAKOTSUBO SYNDROME
- PO 210 INTERTAK PROGNOSTIC SCORE - A USEFUL TOOL TO PREDICT MORTALITY IN TAKOTSUBO SYNDROME?
- PO 214 IMPACT OF NEW-ONSET ATRIAL FIBRILLATION ON PROGNOSIS IN TAKOTSUBO SYNDROME

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.1 VALVULAR HEART DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

- CO 6 SUBENDOCARDIAL "ISCHEMIC-LIKE" STATE IN PATIENTS WITH SEVERE AORTIC STENOSIS: INSIGHTS FROM MYOCARDIAL HISTOPATHOLOGY AND ULTRASTRUCTURE
- CO 7 SEX DIFFERENCES IN AORTIC STENOSIS PROGRESSION AND CARDIAC DAMAGE
- CO 8 LEFT VENTRICULAR DYSFUNCTION IN PATIENTS WITH AORTIC STENOSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS,
OUTCOME**

- PO 312 PREVALENCE, PREDICTORS AND PROGNOSTIC SIGNIFICANCE OF ACUTE KIDNEY RECOVERY FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 340 CONSERVATIVE APPROACH FOR SIGNIFICANT VALVULAR HEART DISEASE - HOW GRIM IS THE PROGNOSIS?
- PO 341 PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH SEVERE AORTIC STENOSIS AWAITING AORTIC VALVE REPLACEMENT

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS**

- CO 10 AORTIC DP/DT AS A NEW TOOL FOR PREDICTION OF AORTIC STENOSIS PROGRESSION: A VALIDATION IN A SINGLE-CENTRE COHORT

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT**

- CO 12 CLINICAL OUTCOMES OF NON-SEVERE PARAVALVULAR LEAK AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- CO 15 DIFFERENCES IN OUTCOMES BETWEEN PERCUTANEOUS CORONARY INTERVENTION OF CORONARY LESIONS AND MEDICAL THERAPY IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- CO 81 TRICUSPID TRANSCATHETER EDGE-TO-EDGE REPAIR (TEER): RIGHT VENTRICLE (RV) FUNCTION AND RV-PULMONARY ARTERY (RV-PA) COUPLING CHARACTERIZATION IN A REAL-WORLD SETTING
- CO 84 CAPL-SCORE: ANTICIPATING FUTILITY IN TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)
- CO 91 TECHNIQUE OF MINISTERNOTOMY IN AORTIC VALVE REPLACEMENT. DOES INTRAOPERATIVE CONVERSION TO FULL STERNOTOMY INCREASE MORBIDITY AND MORTALITY? A SINGLE CENTER ANALYSIS
- PO 309 PERCUTANEOUS CORONARY REVASCLARIZATION TIMING IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 310 TAVI VS AORTIC VALVE REPLACEMENT SURGERY: COMPARISON OF IN-HOSPITAL OUTCOMES IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 311 CLINICAL INSIGHTS: ULTRASOUND-GUIDED FEMORAL PUNCTURE IN TRANSCATHETER AORTIC VALVE REPLACEMENT - A COMPREHENSIVE ANALYSIS OF VASCULAR COMPLICATIONS AND MORTALITY RATES
- PO 337 OUTCOMES OF VALVE-IN-VALVE AND VALVE-IN-RING PROCEDURES FOLLOWING 1.6 YEARS OF FOLLOW-UP
- PO 338 TRICUSPID INTERVENTION FOR SEVERE TRICUSPID REGURGITATION IN PATIENTS WITH CARDIAC IMPLANTABLE ELECTRONIC DEVICES - MANAGEMENT, FATE OF LEADS AND OUTCOMES
- PO 339 IMPACTO DO TEMPO DE ESPERA NOS DOENTES EM LISTA PARA SUBSTITUIÇÃO VALVULAR AÓRTICA
- PO 348 CUSP-OVERLAP TECHNIQUE TO REDUCE PERMANENT PACEMAKER IMPLANTATION RATE AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 350 INTRODUCTION OF A MINIMALLY INVASIVE MITRAL VALVE PROGRAM. A SINGLE CENTER ANALYSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.5 VALVULAR HEART DISEASE - PREVENTION**

- PO 342 ANTICOAGULATION FOLLOWING VALVE-IN-VALVE, VALVE-IN-RING AND VALVE-IN-MAC - A SYSTEMATIC REVIEW WITH METAANALYSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.7 VALVULAR HEART DISEASE - OTHER**

- PO 347 EXPLORING ATRIOVENTRICULAR CONDUCTION DISTURBANCES AND VENTRICULAR PACING RATE IN PATIENTS WITH PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 285 COMORBIDITY AND PROGNOSIS IN OCTOGENARIANS WITH INFECTIVE ENDOCARDITIS
- PO 286 INFECTIVE ENDOCARDITIS - SEX DIFFERENCES
- PO 287 LANDSCAPE OF INFECTIVE ENDOCARDITIS IN A PORTUGUESE TERTIARY CENTER: DEMOGRAPHIC TRENDS, RISK PROFILES AND CLINICAL VARIABILITY
- PO 290 PREDICTORS OF EMBOLIC EVENTS IN INFECTIVE ENDOCARDITIS - REALITY IN PORTUGUESE CENTER
- PO 291 UNDERSCORING THE NEED FOR INFECTIVE ENDOCARDITIS RISK STRATIFICATION AND MANAGEMENT
- PO 293 INFECTIVE ENDOCARDITIS IN ELDERLY - PREDICTORS OF 1 YEAR MORTALITY

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 16. INFECTIVE ENDOCARDITIS -> 16.3 INFECTIVE ENDOCARDITIS - DIAGNOSTIC METHODS

- PO 288 RELATIVE CONTRIBUTION OF IMAGING TECHNIQUES FOR THE CONTEMPORARY DIAGNOSIS OF INFECTIVE ENDOCARDITIS: A SINGLE-CENTER EXPERIENCE

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 16. INFECTIVE ENDOCARDITIS -> 16.5 INFECTIVE ENDOCARDITIS - PREVENTION

- PO 289 INFECTIVE ENDOCARDITIS RISK IN PATIENTS WITH BICUSPID AORTIC VALVE: SYSTEMATIC REVIEW AND META-ANALYSIS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 16. INFECTIVE ENDOCARDITIS -> 16.6 INFECTIVE ENDOCARDITIS - CLINICAL

- PO 292 IMPACT OF ACUTE HEART FAILURE IN INFECTIVE ENDOCARDITIS: A REAL-WORLD STUDY

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- CO 61 UNRAVELING THE COMPLEXITY OF HYPERTROPHIC CARDIOMYOPATHY: A MACHINE LEARNING-BASED RADIOMICS MODEL TO PREDICT PHENOTYPE AND CARDIOVASCULAR EVENTS
- PO 72 ASSESSING MYOCARDIAL RECOVERY AND VENTRICULAR REMODELING AFTER ACUTE MYOCARDITIS
- PO 73 DO CARDIAC BIOMARKERS PREDICT SHORT AND LONG-OUTCOMES IN ACUTE MYOCARDITIS? RESULTS OF A LONG-TERM PROSPECTIVE STUDY
- PO 75 WHAT IS THE LONG-TERM PROGNOSIS OF ACUTE MYOCARDITIS? RESULTS OF A LONG-TERM PROSPECTIVE STUDY
- PO 92 TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH COEXISTENT CARDIAC AMYLOIDOSIS
- PO 106 OUTCOMES OF FAMILY SCREENING FOR HEREDITARY CARDIAC DISEASES SCREENING - GENETIC CONFIRMED CARDIOMYOPATHY OR ARRHYTHMIA AS MODELS FOR PRIMARY PREVENTION
- PO 107 DIFFERENT VARIANTS, SAME GENE: SIMILAR OR DIFFERENT EVOLUTIONARY BEHAVIOR THROUGHOUT LIFE?
- PO 111 UPTAKE OF GENETIC COUNSELLING AND GENETIC TESTING IN INHERITED CARDIOMYOPATHIES AND ARRHYTHMIAS IN A PORTUGUESE REFERENCE GENETIC DEPARTMENT
- PO 294 TIME-TRENDS IN THE DECISION OF A PRIMARY PREVENTION STRATEGY IMPLEMENTATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 295 CLINICAL OUTCOMES IN A POPULATION WITH HYPERTROPHIC CARDIOMYOPATHY AND MYBPC3 GENE DISEASE: THE SHORT VERSION OF A LONG HISTORY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS**

- CO 64 LEFT VENTRICULAR TRANSRADIAL ENDOMYOCARDIAL BIOPSY IN VAL30MET PATIENTS AND NEGATIVE BONE SCINTIGRAPHY: CHANGING DIAGNOSTIC PARADIGM
- CO 65 REFINING THE DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY WITH A MACHINE LEARNING-BASED RADIOMICS MODEL: A CARDIOVASCULAR MAGNETIC RESONANCE STUDY
- CO 86 MACHINE-LEARNING BASED RADIOMICS MODEL TO PREDICT VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- CO 90 THE USE OF LATE GADOLINIUM ENHANCEMENT TO IMPROVE THE YIELD OF GENETIC TESTING IN DILATED CARDIOMYOPATHY
- PO 74 SAMY SCORE: A DISCRIMINATIVE TOOL FOR DISTINGUISHING MYOCARDITIS FROM ACUTE CORONARY SYNDROME
- PO 89 CHARACTERIZATION OF PATIENTS WITH CARDIAC AMYLOIDOSIS DIAGNOSED AT THE TIME OF IDIOPATHIC CARPAL TUNNEL SURGERY
- PO 156 CORRELATION BETWEEN AUTOMATICALLY OBTAINED LONGITUDINAL SHORTENING OF THE LEFT VENTRICLE AND THE PRESENCE OF LATE ENHANCEMENT ON CMR
- PO 297 ASSESSMENT OF ECG AS A SCREENING TOOL FOR HYPERTROPHIC CARDIOMYOPATHY: ADEQUACY AND PHENOTYPIC CORRELATIONS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.4 MYOCARDIAL DISEASE - TREATMENT**

- CO 89 TAFAMIDIS FOR THE TREATMENT OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS (ATTR-CM) - REAL-WORLD DATA FROM A TERTIARY CENTER
- PO 88 SGLT2 INHIBITORS IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: WHAT TO EXPECT?
- PO 90 THERAPEUTIC VALUE OF SPIRONOLACTONE IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- PO 91 12-MONTH EFFECT OF TAFAMIDIS ON THE CLINICAL PROGRESSION OF CARDIAC AMYLOIDOSIS IN A SINGLE CENTRE COHORT
- PO 93 SGLT2I ON TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A NEW DRUG FOR AN UNDER-RECOGNIZED CARDIOMYOPATHY
- PO 109 CARDIAC INVOLVEMENT AFTER LIVER TRANSPLANTATION IN FAMILIAL AMYLOID POLYNEUROPATHY - A CONTINUING CHALLENGE
- PO 298 MAVACAMTEN IN A REAL-WORLD HYPERTROPHIC CARDIOMYOPATHY (HCM) POPULATION: HOW MANY MAY BE ELIGIBLE?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.5 MYOCARDIAL DISEASE - PREVENTION**

- PO 300 PREDICTION OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL**

- PO 14 IMPLANTABLE LOOP RECORDER MONITORING IN CARDIOMYOPATHIES: UNVEILING CLINICALLY RELEVANT ARRHYTHMIAS
- PO 296 MYOCARDIAL BRIDGING IN HYPERTROPHIC CARDIOMYOPATHY: PREVALENCE, CHARACTERISTICS, AND CLINICAL IMPLICATIONS
- PO 299 CLINICAL PROFILE AND OUTCOMES OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY ASSOCIATED WITH MUTATIONS IN THE MYH7 GENE: A LONG LONGITUDINAL FOLLOW UP STUDY
- PO 301 HYPERTROPHIC CARDIOMYOPATHY AND CORONARY ARTERY DISEASE: PREVALENCE, CHARACTERISTICS, AND IMPLICATIONS IN THE CONTEXT OF EVOLVING PHYSICAL EXERCISE RECOMMENDATIONS
- PO 302 THE PHENOTYPIC EXPRESSION OF HYPERTROPHIC CARDIOMYOPATHY - INSIGHTS FROM A POPULATION WITH PATHOGENIC MUTATIONS IN THE MYBPC3 GENE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART
DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 110 RASOPATHIES - CARDIAC MANIFESTATIONS AND OUTCOMES IN A TERTIARY CENTER COHORT STUDY
- PO 322 THE DUAL CHALLENGE: UNDERSTANDING AND MANAGING PULMONARY HYPERTENSION IN CONGENITAL HEART DEFECTS
- PO 323 PREDICTORS OF SUPRAVENTRICULAR ARRHYTHMIAS IN ADULTS WITH EBSTEIN ANOMALY
- PO 326 PULMONARY REGURGITATION IN TETRALOGY OF FALLOT - THE EXPERIENCE OF A SINGLE TERTIARY CENTER

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.3 CONGENITAL HEART
DISEASE - DIAGNOSTIC METHODS**

- PO 324 EVALUATION OF FETAL CARDIAC FUNCTION IN GESTATIONAL DIABETES MELLITUS BY TWO-DIMENSIONAL SPECKLE-TRACKING TECHNOLOGY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.4 CONGENITAL HEART
DISEASE - TREATMENT**

- PO 321 ARNI TREATMENT IN ADULTS WITH TETRALOGY OF FALLOT - A SINGLE-CENTRE EXPERIENCE
- PO 325 SACUBITRIL/VALSARTAN IN ADULTS WITH CONGENITAL HEART DISEASE AND DEPRESSED VENTRICLE FUNCTION

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.2 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - EPIDEMIOLOGY,
PROGNOSIS, OUTCOME**

- CO 56 LONG-TERM EXERCISE TOLERANCE AND QUALITY OF LIFE AFTER BALLOON PULMONARY ANGIOPLASTY (BPA): IS THERE A ROLE FOR RIGHT HEART CATHETERIZATION?
- PO 7 PERFORM SCORE: A PROGNOSTIC TOOL FOR PREDICTING NEED FOR FIBRINOLYSIS IN PULMONARY EMBOLISM
- PO 8 SERUM ALKALINE PHOSPHATASE AS A RISK-STRATIFICATION TOOL IN PULMONARY EMBOLISM
- PO 12 POOR PROGNOSIS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM TREATED WITH MECHANICAL THROMBECTOMY
- PO 37 THE UNUSUAL SUSPECT - IS PULMONARY VENO-OCCLUSIVE DISEASE UNDERRECOGNIZED?
- PO 39 FOUR-STRATA RISK-ASSESSMENT TOOL FOR PULMONARY HYPERTENSION: CAN WE ASSOCIATE IT WITH HAEMODYNAMIC PARAMETERS?
- PO 41 GENETIC TESTING IN PAH: ASSESSING CLINICAL RISK AND PROGNOSTIC SIGNIFICANCE OF MUTATIONS
- PO 43 CONNECTIVE TISSUE DISEASE AND PULMONARY HYPERTENSION - AN OMINOUS ASSOCIATION
- PO 44 FOUR STRATA RISK STRATIFICATION IN PULMONARY ARTERIAL HYPERTENSION: IS IT REALLY ENOUGH?
- PO 45 ASSESSING THE ARTERIAL-VENTRICULAR UNCOUPLING IN PULMONARY ARTERIAL HYPERTENSION - IS THERE A PLACE FOR STROKE VOLUME INDEX?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->
21.3 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC
METHODS**

- CO 57 UNMASKING EXERCISE PULMONARY HYPERTENSION - DOES TIME MATTER?
- CO 87 RIGHT VENTRICULAR MYOCARDIAL WORK: PROOF-OF-CONCEPT FOR NON-INVASIVE ASSESSMENT OF RIGHT VENTRICULAR FUNCTION IN PULMONARY HYPERTENSION PATIENTS

PO 38 ECHOCARDIOGRAPHIC INSIGHTS REDEFINING RISK IN PULMONARY ARTERIAL HYPERTENSION: A FOCUS ON RIGHT ATRIAL VOLUME INDEX FOR ENHANCED STRATIFICATION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.4 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - TREATMENT

CO 58 ENDARTERECTOMY IN CTEPH - HEMODYNAMIC IMPROVEMENT AND RV/PA COUPLING

CO 59 WHITE SMOKE IN THE INTERMEDIATE RISK PE DEBATE - COULD POPE BE THE SOLUTION?

PO 9 RESIDUAL PULMONARY HYPERTENSION AFTER PEA - AN ILL-DEFINED PROBLEM

PO 10 BALLOON PULMONARY ANGIOPLASTY IN CTEPH - READY FOR THE FRONTLINE?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.6 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - CLINICAL

PO 11 PREVALENCE AND PREDICTORS OF NORMOTENSIVE CARDIOGENIC SHOCK IN INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.7 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - OTHER

PO 40 ASSESSING INVASIVE HEMODYNAMICS IN PULMONARY HYPERTENSION: EXAMINING THE PREDICTIVE UTILITY OF CARBOHYDRATE ANTIGEN 125 AND N-TERMINAL PRO-BRAIN-TYPE NATRIURETIC PEPTIDE

PO 42 ESTUDO SHAPE - UMA PRIMEIRA FOTOGRAFIA À REALIDADE DA HIPERTENSÃO ARTERIAL PULMONAR EM PORTUGAL

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE -> 22.1 AORTIC DISEASE - PATHOPHYSIOLOGY AND MECHANISMS

CO 34 THE EFFECT OF THE LPA GENE ON AORTIC VALVE CALCIFICATION IN A PORTUGUESE POPULATION

G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE -> 22.4 AORTIC DISEASE - TREATMENT

CO 9 TWO DECADES OF EFFECTIVE STENT IMPLANTATION IN AORTIC COARCTATION PATIENTS: A SINGLE-CENTER COHORT STUDY OF LONG-TERM HYPERTENSIVE BURDEN

CO 93 LONG-TERM OUTCOME OF ACUTE TYPE A AORTIC DISSECTIONS: A 20-YEAR SINGLE-CENTER CASUISTIC

PO 98 ACUTE AORTIC SYNDROMES IN A CENTER WITHOUT ON-SITE CARDIAC SURGERY

PO 99 ACUTE STANFORD TYPE A AORTIC DISSECTIONS - THE EXPERIENCE OF AN ULTRA-PERIPHERAL CENTER

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.1 INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT

CO 63 INVASIVE QUANTITATIVE ASSESSMENT OF CORONARY MICROVASCULAR DYSFUNCTION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

PO 188 PHYSIOLOGY VERSUS ANGIOGRAPHY-GUIDED CORONARY ARTERY BYPASS GRAFTING: A SYSTEMATIC REVIEW AND META-ANALYSIS

PO 272 COMPREHENSIVE ASSESSMENT OF LEFT MAIN CORONARY ARTERY STENOSIS UTILIZING PRESSURE WIRE: A RETROSPECTIVE ANALYSIS

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.2 CORONARY INTERVENTION

- PO 186 INVASIVE TREATMENT WITHOUT STENTING IN ACUTE MYOCARDIAL INFARCTION: "NO STENT" EXPERIENCE IN SINGLE CENTRE
- PO 194 BIOABSORBABLE VASCULAR SCAFFOLDS IN CLINICAL PRACTICE: NOT AS BAD AS ONE MIGHT EXPECT
- PO 275 THE INFLUENCE OF CARDIOVASCULAR RISK FACTORS ON RESTENOSIS AND MORTALITY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN DISEASE

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION

- CO 11 TAVI FOR TREATING SEVERE AORTIC VALVE DISEASE IN CARDIOGENIC SHOCK - A SINGLE CENTRE EXPERIENCE
- CO 13 TAVI VS BALLON AORTIC VALVULOPLASTY IN ACUTE DECOMPENSATED AORTIC STENOSIS
- CO 14 TIMING OF PCI IN TAVR PATIENTS IMPACT CLINICAL OUTCOMES
- CO 22 AIMING-PACE: ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING-BASED PREDICTION MODEL FOR PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 1 LEFT ATRIAL APPENDAGE CLOSURE: DOES SHAPE MATTER?
- PO 2 BALLOON PULMONARY ANGIOPLASTY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: SAFETY AND PROCEDURAL TOLERANCE IN ELDERLY PATIENTS
- PO 5 LEFT VENTRICULAR TRANSRADIAL ENDOMYOCARDIAL BIOPSY: A SAFE AND EFFECTIVE APPROACH
- PO 6 CORONARY SINUS REDUCER DEVICE FOR THE TREATMENT OF REFRACTORY ANGINA. A SINGLE CENTRE EXPERIENCE
- PO 52 TRANSCATHETER AORTIC VALVE REPLACEMENT AND BICUSPID AORTIC VALVE
- PO 53 SURVIVAL IN VERY ELDERLY PATIENTS SUBMITTED TO TAVI COMPARED TO THE GENERAL POPULATION
- PO 54 OUTCOMES OF INFECTIVE ENDOCARDITIS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION VERSUS AORTIC VALVE REPLACEMENT SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 55 30-DAY AND 1-YEAR MORTALITY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: THE IMPACT OF BALLOON AORTIC VALVULOPLASTY AS A BRIDGING THERAPY IN A TERTIARY CENTER
- PO 56 CONTRACTILE RESERVE AND SURVIVAL OUTCOMES IN TRANSCATHETER AORTIC VALVE IMPLANTATION FOR LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS
- PO 57 ORAL ANTICOAGULATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 147 RISK FACTOR ANALYSIS OF PERMANENT PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 148 UNMET NEEDS IN TRANSCATHETER AORTIC VALVE REPLACEMENT: A NOVEL TELEMETRY PATCH FOR MONITORING CONDUCTION DISTURBANCES
- PO 149 DE NOVO CONDUCTION DISTURBANCES AFTER TAVI: WHAT TO EXPECT?
- PO 150 NON-CORONARY CUSP ASYMMETRICAL CALCIFICATION AS A PREDICTOR OF COMPLETE ATRIOVENTRICULAR BLOCK POST-TAVI
- PO 151 NEW-ONSET LEFT BUNDLE BRANCH BLOCK AFTER TAVI: UNVEILING ITS TRUE CLINICAL IMPACT
- PO 152 IMPACT OF RHYTHM DISTURBANCES IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION UNDERGOING TAVI
- PO 165 VIABAHN STENTS FOR TREATING TAVI-RELATED VASCULAR ACCESS COMPLICATIONS - A SINGLE-CENTRE EXPERIENCE
- PO 166 SECONDARY ACCESS IN TAVR: ENHANCING SAFETY AND SIMPLIFYING VASCULAR COMPLICATIONS RESOLUTION
- PO 167 VASCULAR COMPLICATIONS AFTER TRANSFEMORAL TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH SMALL PERIPHERAL VESSELS
- PO 168 VALVE-IN-VALVE TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH FAILED BIOPROSTHETIC AORTIC VALVES: AN ANALYSIS OF SAFETY, FEASIBILITY AND CLINICAL OUTCOMES
- PO 343 POST- TAVI CARE: ASSESSING THE NEED FOR CARDIAC DEVICE IMPLANTATION
- PO 344 POST-TAVI MYOCARDIAL INJURY: DEFINING A DIAGNOSIS
- PO 351 FUNCTIONAL MITRAL REGURGITATION IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A COMPREHENSIVE SINGLE-CENTER STUDY

- PO 352 CAN ELDERLY PATIENTS WITH SEVERE MITRAL REGURGITATION BE IDEAL CANDIDATES FOR MITRACLIP?
- PO 353 THE EFFECTS OF MITRACLIP FOR SEVERE MITRAL REGURGITATION ON RIGHT VENTRICULAR FUNCTION AND REMODELLING
- PO 354 MITRAL TRANSCATHETER EDGE-TO-EDGE REPAIR: 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.4 INTERVENTIONAL CARDIOLOGY - OTHER

- PO 3 SAME-DAY DISCHARGE AFTER ELECTIVE PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE
- PO 4 CAROTID ARTERY STENTING: A DESCRIPTIVE ANALYSIS OF A TERTIARY HOSPITAL'S EXPERIENCE
- PO 46 REAMING AT RESISTANT HYPERTENSION: OLD WEAPONS BROUGHT BACK.
- PO 169 LONG-TERM CLINICAL AND IMAGING OUTCOMES OF PATIENTS UNDERGOING PERCUTANEOUS FEMORAL INTERVENTION FOLLOWING TAVI-RELATED VASCULAR ACCESS COMPLICATIONS
- PO 170 MANTA VASCULAR CLOSURE DEVICE: CARDIOVASCULAR RISK FACTORS AND COMPLICATIONS IN A SINGLE-CENTER STUDY
- PO 313 ENVIRONMENTAL IMPACT OF PERCUTANEOUS AORTIC VALVE IMPLANTS. PROCEDURE ASSESSMENT
- PO 345 IMPACT OF TRANSCATHETER AORTIC VALVE IMPLANTATION ON KIDNEY FUNCTION IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 346 AORTIC VALVE CALCIFICATION AS A SURROGATE PARAMETER FOR PARAVALVULAR REGURGITATION FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 349 EXPLORATORY ANALYSIS OF CLINICAL OUTCOMES IN PATIENTS WITH SECONDARY MITRAL REGURGITATION: THE IMPACT OF COAPT TRIAL CRITERIA

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.1 CARDIOVASCULAR SURGERY - CORONARY ARTERIES

- PO 159 LONG-TERM SURVIVAL AFTER CORONARY ARTERY BYPASS GRAFTING: COMPARING BILATERAL VERSUS SINGLE INTERNAL MAMMARY ARTERY IN A WOMEN COHORT
- PO 160 CORONARY ARTERY BYPASS GRAFTING COULD EXTEND SURVIVAL IN OCTOGENARIAN PATIENTS
- PO 161 BRIDGING THE GAP: A COMPREHENSIVE META-ANALYSIS ON SURGICAL REVASCLARIZATION FOR CHRONIC CORONARY TOTAL OCCLUSIONS
- PO 162 LONG-TERM OUTCOMES OF DELAYED PERCUTANEOUS INTERVENTION VERSUS SAPHENOUS VEIN GRAFT FOR REVASCLARIZING THE RIGHT CORONARY ARTERY
- PO 164 THE IMPACT OF SEX ON LONG-TERM SURVIVAL AFTER CORONARY ARTERY BYPASS GRAFTING: 19-YEARS OF FOLLOW-UP

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.2 CARDIOVASCULAR SURGERY - VALVES

- CO 92 SURGICAL AORTIC VALVE REPLACEMENT FOLLOWING DECLINED TRANSCATHETER AORTIC VALVE IMPLANTATION

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.8 CARDIOVASCULAR SURGERY - TRANSPLANTATION

- CO 5 PREDICTORS OF ACUTE HEART TRANSPLANT REJECTION

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.9 CARDIOVASCULAR SURGERY - ARRHYTHMIAS

- PO 378 SURGICAL ABLATION OF ATRIAL FIBRILLATION CONCOMITANT WITH VALVULAR SURGERY: IS IT WORTHED?

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.10 CARDIOVASCULAR SURGERY - MINIMALLY INVASIVE SURGERY

CO 54 MINI-INVASIVE SURGICAL ABLATION AS AN ALTERNATIVE FOR TREATING ATRIAL FIBRILLATION RECURRENCE AFTER CATHETER ABLATION

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.11 CARDIOVASCULAR SURGERY - OTHER

PO 163 PREDICTORS OF PROLONGED HOSPITALIZATION AFTER CARDIAC SURGERY: INSIGHTS FROM A RETROSPECTIVE STUDY

I. HYPERTENSION -> 27. HYPERTENSION -> 27.2 HYPERTENSION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 47 SIGNIFICANCE OF NOCTURNAL DIASTOLIC BLOOD PRESSURE IN PREDICTING OUTCOMES IN HYPERTENSIVE DISORDERS OF PREGNANCY

PO 48 AMBULATORY PULSE PRESSURE MONITORING AS A PROGNOSTIC INDICATOR FOR CARDIOVASCULAR EVENTS IN A HYPERTENSIVE POPULATION

PO 119 THE GENETIC POLYMORPHISM OF ALPHA-ADDUCIN 1 IS ASSOCIATED WITH INCREASED ARTERIAL STIFFNESS IN A DIABETIC POPULATION

I. HYPERTENSION -> 27. HYPERTENSION -> 27.3 HYPERTENSION - DIAGNOSTIC METHODS

PO 49 UNRAVELING THE STRUCTURAL AND FUNCTIONAL ADAPTATIONS IN HYPERTENSIVE HEART DISEASE: WHAT LIES BEYOND LEFT VENTRICULAR HYPERTROPHY?

I. HYPERTENSION -> 27. HYPERTENSION -> 27.4 HYPERTENSION - TREATMENT

PO 50 LONG-TERM OUTCOMES AFTER RENAL DENERVATION: A FOLLOW-UP OF 5 YEARS

PO 51 BASELINE RENIN LEVELS AND THE EFFICACY OF MINERALOCORTICOID INHIBITORS: A META-ANALYSIS

I. HYPERTENSION -> 27. HYPERTENSION -> 27.7 HYPERTENSION - OTHER

PO 118 FIBRINOGEN IS ASSOCIATED TO INCREASED ARTERIAL STIFFNESS ON HYPERTENSIVE INDIVIDUALS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY

CO 27 ENHANCING PRIMARY PREVENTION: THE INCREMENTAL PREDICTIVE VALUE OF NTPROBNP BEYOND ASCVD RISK ASSESSMENT

PO 171 OPTIMIZING CARDIAC REHABILITATION ADHERENCE: UNVEILING THE POTENTIAL OF REMOTE CARDIAC TELEREHABILITATION

PO 225 CARDIOMYOPATHIES: THE IMPORTANCE OF GENETIC TESTING IN THE ELDERLY

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT

PO 142 DIGITAL SELF-REPORTED CARDIOVASCULAR RISK FACTORS IN A SAMPLE OF THE PORTUGUESE POPULATION - PRELIMINARY RESULTS FROM THE RADICAL STUDY

PO 143 WHICH IS BETTER FOR PREDICTING AND DISCRIMINATING CARDIOVASCULAR EVENTS: A TRADITIONAL RISK SCORE, A CALCIUM SCORE OR A GENETIC RISK SCORE?

PO 315 SARCOPENIC OBESITY - A HIDDEN PROBLEM IN CARDIOVASCULAR RISK

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION

- PO 65 LIPOPROTEIN(A) ROLE IN ACUTE MYOCARDIAL INFARCTION: REAL-WORLD DATA OF A TERTIARY CARE CENTRE
- PO 66 TARGET LIPID GOALS IN VERY HIGH RISK CARDIOVASCULAR PATIENTS - RESULTS FROM A SECONDARY PREVENTION OUTPATIENT PROGRAM
- PO 144 SECONDARY PREVENTION IN YOUNG PATIENTS AFTER ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION: MISSING THE GOALS AND SUFFERING THE PENALTIES.
- PO 146 ENHANCING CARDIOVASCULAR HEALTH POST-ACUTE CORONARY SYNDROME: A SPECIALIZED FOLLOW-UP PROGRAM

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.4 LIPIDS

- PO 67 DO TRIGLYCERIDES IMPACT CARDIOVASCULAR OUTCOMES? A 10-YEAR FOLLOW UP STUDY FROM A PORTUGUESE COHORT
- PO 68 EFFICACY OF ORAL HYPOLIPIDEMIC THERAPIES IN A REAL WORLD POPULATION
- PO 141 BEYOND GUIDELINES: ACHIEVING RISK FACTORS THERAPEUTIC GOALS THROUGH A STRUCTURED FOLLOW-UP PROGRAM

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.6 OBESITY

- PO 316 PREVALENCE OF ELIGIBILITY CRITERIA FOR SEMAGLUTIDE ACCORDING TO THE SELECT TRIAL IN A PORTUGUESE COHORT OF ACUTE CORONARY SYNDROME
- PO 365 HIGH SCREENING BLOOD PRESSURE IS FOUND IN MOST OBESE PRIMARY SCHOOL CHILDREN FROM THE NORTH OF PORTUGAL: PRELIMINARY RESULTS FROM THE GREAT STUDY.

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.7 DIABETES AND THE HEART

- PO 69 DIABETES MELLITUS INFLUENCE IN LIPOPROTEIN(A) GENE EXPRESSION AND ASSOCIATION TO CORONARY ARTERY DISEASE

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.11 NUTRITION, MALNUTRITION AND HEART DISEASE

- CO 17 MULTIMODAL NUTRITIONAL RISK SCREENING IN HEART FAILURE PATIENTS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.12 PHYSICAL INACTIVITY AND EXERCISE

- PO 224 PHYSICAL ACTIVITY LEVELS AND SEDENTARY BEHAVIOUR PATTERNS IN PATIENTS ATTENDING A PHASE III CARDIAC REHABILITATION PROGRAM: ARE THERE DIFFERENCES BETWEEN MEN AND WOMEN?

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.14 RISK FACTORS AND PREVENTION - OTHER

- CO 28 ENHANCING PRIMARY PREVENTION: THE INCREMENTAL PREDICTIVE VALUE OF HSTNT BEYOND ASCVD RISK ASSESSMENT
- PO 64 IS THE TRIGLYCERIDE GLUCOSE INDEX A VALUABLE MARKER IN THE EARLY IDENTIFICATION OF CARDIOVASCULAR EVENTS?
- PO 145 CARDIOGAP: BRIDGING THE GAP BETWEEN PATIENT IDENTIFICATION AND THERAPY IMPLEMENTATION IN CARDIOVASCULAR RISK

- PO 157** IS HOMOCYSTEINE AN INDEPENDENT RISK FACTOR FOR SUBCLINICAL CORONARY ATHEROSCLEROSIS IN ASYMPTOMATIC INDIVIDUALS?

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.1 EXERCISE TESTING

- CO 18** WHAT IS THE TRUE NORMAL: COMPARISON OF DIFFERENT EQUATIONS FOR ESTIMATING PEAK OXYGEN UPTAKE FOR OUTCOME PREDICTION IN HEART FAILURE
- CO 19** EARLY OXYGEN PULSE PLATEAU AS A PROGNOSTIC MARKER IN A POPULATION OF PATIENTS WITH HEART FAILURE: HOW SOON IS TOO SOON?
- PO 317** EXCEEDING THE THRESHOLDS: CHARACTERIZATION AND CLINICAL IMPACT OF THE THIRD VENTILATORY THRESHOLD IN PATIENTS WITH HEART FAILURE
- PO 376** HEART RATE CORRECTED PEAK O₂ PULSE AS A SIGNIFICANT PREDICTOR OF CARDIOVASCULAR ADVERSE EVENTS IN HEART FAILURE PATIENTS

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION

- CO 20** CARDIAC REHABILITATION IN YOUNG PATIENTS POST ACUTE CORONARY SYNDROME: THE KEYSTONE IN CARDIOVASCULAR CARE
- PO 172** IMPROVED EXERCISE CAPACITY AND CARDIAC EVENTS AFTER REHABILITATION IN POST-ACUTE CORONARY SYNDROME PATIENTS
- PO 173** BEYOND PHASE 2: THE IMPACT OF PHASE 3 CARDIAC REHABILITATION ON PHYSICAL ACTIVITY
- PO 174** CHRONOTROPIC INCOMPETENCE - STILL ON TIME TO MAKE A DIFFERENCE ?
- PO 175** CARDIOVASCULAR REHABILITATION - DETERMINANTS OF LONG-TERM OUTCOMES
- PO 176** POST-CARDIAC REHABILITATION CONCERNS: CAN CHRONIC HEART FAILURE PATIENTS SUSTAIN HEALTH GAINS DURING PHASE III?
- PO 227** HANDGRIP STRENGTH AND MUSCLE MASS GAINS IN PHASE III CARDIAC REHABILITATION PATIENTS - IMPACT OF WEEKLY EXERCISE TRAINING FREQUENCY
- PO 318** EXERCISE INTENSITY PRESCRIPTION IN HEART FAILURE PATIENTS: COMPARISON OF DIFFERENT PHYSIOLOGICAL PARAMETERS
- PO 319** THE IMPACT OF CARDIAC REHABILITATION ON MUSCLE STRENGTH - A CRUCIAL ELEMENT OF FUNCTIONAL CAPACITY
- PO 369** SEX DIFFERENCES IN LONG-TERM ATTENDANCE AND DROPOUT RATES IN PHASE III CARDIOVASCULAR REHABILITATION PROGRAMS

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.3 SPORTS CARDIOLOGY

- CO 95** CORONARY ATHEROSCLEROTIC BURDEN IN MASTER ATHLETES: RELATIONSHIP WITH CARDIOVASCULAR RISK AND VOLUME OF EXERCISE
- PO 320** SUDDEN CARDIAC DEATH IN ATHLETES: A 20-YEAR ANALYSIS IN PORTUGAL

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.2 CARDIOVASCULAR DISEASE IN WOMEN

- CO 72** ACUTE CORONARY SYNDROMES: DISPARITIES IN THE INITIAL APPROACH FOR MEN AND WOMEN
- CO 73** GENDER DISPARITIES IN ACUTE CORONARY SYNDROMES: A COMPREHENSIVE ANALYSIS OF MANAGEMENT, TREATMENT, AND PROGNOSIS
- PO 368** HEART FAILURE DISPARITIES BY SEX: A COMPARATIVE ANALYSIS OF A REAL-WORLD POPULATION FOLLOWED IN A REGIONAL HOSPITAL

- PO 370 SEX-RELATED DIFFERENCES IN CONDUCTION DISTURBANCES AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
PO 371 SEX-BASED DIFFERENCES IN INFECTIVE ENDOCARDITIS: A REAL-WORLD STUDY

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.5 CARDIOVASCULAR DISEASE IN THE ELDERLY

- PO 16 DIAGNOSTIC YIELD OF 24-HOUR HOLTER MONITORING IN NONAGENARIANS - INSIGHTS FROM A SINGLE-CENTER COHORT
PO 17 LEFT ATRIAL APPENDAGE CLOSURE (LAA): A COMPREHENSIVE ANALYSIS OF PERIPROCEDURAL AND LONG-TERM OUTCOMES IN ELDERLY PATIENTS.
PO 18 BEYOND 55: CLINICAL PERSPECTIVES ON TRANSCATHETER PFO CLOSURE - INSIGHTS FROM A UNICENTER STUDY
PO 95 PACEMAKER IMPLANTATION IN THE ELDERLY: CAN THE PATIENT'S LEVEL OF DEPENDENCE SELECT THE BEST CANDIDATES FOR DEVICE IMPLANTATION?

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOLOGY

- PO 76 CANCER THERAPY-RELATED CARDIOVASCULAR TOXICITY: WHAT'S THE ACCURACY OF BASELINE CARDIOVASCULAR RISK STRATIFICATION IN THE PREDICTION OF ITS OCCURRENCE?
PO 79 ARE STATINS PREVENTIVE OF CARDIOTOXICITY IN BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES? A SINGLE CENTER RETROSPECTIVE ANALYSIS
PO 80 MORBIDITY AND MORTALITY OF CARDIO-ONCOLOGY PATIENTS: IS THERE ANY LINK TO BASELINE CARDIOVASCULAR RISK?
PO 81 ¹⁸F-FDG UPTAKE AS A SURROGATE MARKER OF VASCULAR DISEASE IN BREAST CANCER: THE ROLE OF ROUTINE EXAMS IN CARDIOVASCULAR RISK EVALUATION

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.7 PREGNANCY AND CARDIOVASCULAR DISEASE

- PO 77 CHARACTERIZATION OF LEFT ATRIAL FUNCTION DURING CARDIAC REMODELING AND REVERSE REMODELING INDUCED BY PREGNANCY
PO 78 IMPACT OF CARDIOVASCULAR RISK FACTORS IN CARDIAC REMODELLING AND REVERSE REMODELLING INDUCED BY PREGNANCY
PO 222 RIGHT CARDIOVASCULAR REMODELLING AND REVERSE REMODELLING DURING PREGNANCY AND POSTPARTUM
PO 372 PREGNANCY AS A MODEL TO EXPLORE STRETCH-INDUCED COMPLIANCE MECHANISM IN PHYSIOLOGICAL HYPERTROPHY

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.9 RENAL FAILURE AND CARDIOVASCULAR DISEASE

- PO 97 FLUID OVERLOAD AT THE BEGINNING OF PERITONEAL DIALYSIS AND ITS ASSOCIATION WITH SERUM NT-PROBNP AND CA-125

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.12 AUTOIMMUNE/CHRONIC INFLAMMATORY DISORDERS AND HEART DISEASE

- PO 71 RISK OF ADVERSE CARDIOVASCULAR EVENTS ACROSS THE GLOBAL LONGITUDINAL STRAIN SPECTRUM IN RHEUMATOID ARTHRITIS PATIENTS

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER

- CO 26 PROCEDURAL AND LONG-TERM PROGNOSIS AFTER SUCCESSFUL CTO RECANALIZATION IN PATIENTS WITH TYPE 2 DIABETES: A UNICENTRIC STUDY
- CO 71 LIPOPROTEIN (A) AS A RISK MARKER FOR WORSE OUTCOMES IN ACUTE MYOCARDIAL INFARCTION PATIENTS
- PO 94 DOES FRAILITY HAVE AN INFLUENCE ON MINOCA?
- PO 121 RECURRENT TRANSFUSION THERAPY IN SICKLE CELL DISEASE - ARE THERE RELEVANT ECHOCARDIOGRAPHIC DIFFERENCES IN THE EVALUATION OF THESE PATIENTS?

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.2 CHRONIC NURSING CARE

- PO 362 CONTRIBUTOS PARA A VALIDAÇÃO DO CORONARY ARTERY DISEASE EDUCATION QUESTIONNAIRE II PARA PORTUGUÊS EUROPEU
- PO 363 PREVALENCE OF SARCOPENIA IN ELDER PATIENTS WITH HEART FAILURE- AN UNDERDIAGNOSED COMORBIDITY
- PO 366 DESENVOLVIMENTO DE UM SISTEMA M-HEALTH PARA A AUTOGESTÃO DO DOENTE COM INSUFICIÊNCIA CARDÍACA: VIVERCOMIC

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER

- PO 361 A HOME-BASED CARDIAC REHABILITATION PROGRAM AIMED AT IMPROVING THEIR CARDIAC CONDITION AND FUNCTIONAL CAPACITY IN PATIENTS WITH LVEF
- PO 364 IS THE BALANCE OF PATIENTS WITH A VENTRICULAR EJECTION FRACTION =40% A VIABLE METRIC FOR ASSESSING THEIR OVERALL HEALTH?

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.4 DIGITAL HEALTH

- CO 55 CATHETER ABLATION FOR ATRIAL FIBRILLATION: UNVEILING KEY PREDICTORS OF LIFE QUALITY ENHANCEMENT

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.1 PUBLIC HEALTH

- PO 108 INTERPRETING GENETIC TESTING FOR INHERITED CARDIAC DISORDERS

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.2 HEALTH POLICY

- PO 58 SMALL CHANGES CAN MAKE A DIFFERENCE: THE IMPACT OF DIFFERENT AJMALINE CHALLENGE PROTOCOLS ON CARBON FOOTPRINT

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 34. PUBLIC HEALTH AND HEALTH ECONOMICS -> 34.3 HEALTH ECONOMICS

- CO 74 EVALUATING ECONOMIC IMPACT OF GENERIC PRASUGREL WIDESPREAD ADOPTION
- PO 226 CUSTOS DA IMPLANTAÇÃO PERCUTÂNEA DE VÁLVULA AÓRTICA E DO SEU COMPARADOR

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 35. RESEARCH METHODOLOGY -> 35.6 RESEARCH METHODOLOGY - OTHER

CO 30 INTEGRATING DIVERSE REAL WORLD DATA FOR ENHANCED PHENOTYPING OF CARDIOVASCULAR CHRONIC CONDITIONS

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.3 BASIC SCIENCE - CARDIAC DISEASES

PO 154 METABOLOMICS AND POOR CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE (HF): A SYSTEMATIC REVIEW AND META-ANALYSIS

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.6 BASIC SCIENCE - OTHER

CO 33 GJA4 GENE INHIBITION MAY REPRESENT A POTENTIAL TARGET FOR NOVEL ANTITHROMBOTIC THERAPIES

CO 35 THE C825T GENETIC VARIANT OF THE G PROTEIN SS3 SUBUNIT IS ASSOCIATED WITH ESSENTIAL HYPERTENSION IN INDIVIDUALS WITH A FAMILY HISTORY OF ESSENTIAL HYPERTENSION

CO 60 IDENTIFICATION OF A MULTI-ETIOLOGICAL SIGNATURE OF HEART FAILURE THROUGH MERGING OF MICROARRAY DATA

PO 153 FTO RS8050136 C>A VARIANT IS A RISK FACTOR FOR METABOLIC SYNDROME IN A PORTUGUESE POPULATION

PO 367 SEX DIFFERENCES IN PLASMA LIPIDOMIC PROFILES OF HEALTHY SUBJECTS AND PATIENTS WITH CARDIOVASCULAR DISEASE

P. OTHER -> 37. MISCELLANEA

CO 70 EVALUATING THE OUTCOMES OF BEDSIDE PERCUTANEOUS PERIPHERAL VA-ECMO DECANNULATION USING A PERCLOSE PROGLIDE SUTURE-MEDIATED POST-CLOSURE PROCEDURE IN A HIGH-VOLUME ECMO CENTRE

PO 59 ATIVIDADE CIENTÍFICA E SATISFAÇÃO GLOBAL NO INTERNATO MÉDICO - A REALIDADE OUTLIER DA CARDIOLOGIA

PO 60 TRENDS AND INSIGHTS INTO CONGENITAL HEART DISEASE EPIDEMIOLOGY IN PORTUGAL: A TWO-DECADE PERSPECTIVE

PO 62 ANÁLISE DA PERSPETIVA DOS JOVENS CARDIOLOGISTAS SOBRE AS ATUAIS MATRIZES DO INTERNATO EM PORTUGAL - RESULTADOS PRELIMINARES

PO 120 HOLTER MONITORING FINDINGS IN NEUROMUSCULAR DISORDERS: FREQUENCY AND IMPORTANCE IN CLINICAL MANAGEMENT